[
  {
    "ts": null,
    "headline": "Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing",
    "summary": "Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination.",
    "url": "https://finnhub.io/api/news?id=7f84e34f6e57ab3a8d93ebc6d364187adbd391679821f24338330bdf87a2f058",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753793520,
      "headline": "Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing",
      "id": 136117778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination.",
      "url": "https://finnhub.io/api/news?id=7f84e34f6e57ab3a8d93ebc6d364187adbd391679821f24338330bdf87a2f058"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated's (NYSE:DGX) Intrinsic Value Is Potentially 79% Above Its Share Price",
    "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Quest Diagnostics fair value estimate is US$300 Quest...",
    "url": "https://finnhub.io/api/news?id=7b3779e811de56d506acfa1d3475e7ba1c2ecf6e95f126c9fda22ceb00be44a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790599,
      "headline": "Quest Diagnostics Incorporated's (NYSE:DGX) Intrinsic Value Is Potentially 79% Above Its Share Price",
      "id": 136117387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Quest Diagnostics fair value estimate is US$300 Quest...",
      "url": "https://finnhub.io/api/news?id=7b3779e811de56d506acfa1d3475e7ba1c2ecf6e95f126c9fda22ceb00be44a5"
    }
  },
  {
    "ts": null,
    "headline": "Quest, Labcorp downplay ‘Big Beautiful Bill’ impact",
    "summary": "Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and domestic policy bill, including cuts to Medicaid, will be minimal.",
    "url": "https://finnhub.io/api/news?id=77ed8e4fa3168e7875be7902abe04404db0bb3065396a49766a010449c9ff653",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790409,
      "headline": "Quest, Labcorp downplay ‘Big Beautiful Bill’ impact",
      "id": 136119811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and domestic policy bill, including cuts to Medicaid, will be minimal.",
      "url": "https://finnhub.io/api/news?id=77ed8e4fa3168e7875be7902abe04404db0bb3065396a49766a010449c9ff653"
    }
  },
  {
    "ts": null,
    "headline": "North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers",
    "summary": "The North America Autoimmune Disease Diagnostics Market is projected to grow from USD 1.96 billion in 2024 to USD 3.5 billion by 2033, at a CAGR of 6.66%. Key growth drivers include rising incidence of autoimmune conditions like rheumatoid arthritis and type 1 diabetes, advancements in diagnostic technologies, and increased healthcare investments. Enhanced diagnostic techniques such as ELISA and next-gen sequencing are improving early detection, with hospitals and clinics expanding sophisticated",
    "url": "https://finnhub.io/api/news?id=e184349c323eaa1227041dd48d800a6db5cea3c58e94a5f94cc637b190910470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753777860,
      "headline": "North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers",
      "id": 136117046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "The North America Autoimmune Disease Diagnostics Market is projected to grow from USD 1.96 billion in 2024 to USD 3.5 billion by 2033, at a CAGR of 6.66%. Key growth drivers include rising incidence of autoimmune conditions like rheumatoid arthritis and type 1 diabetes, advancements in diagnostic technologies, and increased healthcare investments. Enhanced diagnostic techniques such as ELISA and next-gen sequencing are improving early detection, with hospitals and clinics expanding sophisticated",
      "url": "https://finnhub.io/api/news?id=e184349c323eaa1227041dd48d800a6db5cea3c58e94a5f94cc637b190910470"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Quest’s Q2 Earnings Call",
    "summary": "Quest Diagnostics delivered a quarter that surpassed Wall Street’s expectations, with strong results driven by a combination of acquisition contributions and robust organic growth. Management highlighted heightened demand for advanced diagnostic tests and expanded access through new health plan contracts as primary factors behind the performance. CEO Jim Davis pointed to increased test ordering from both physicians and enterprise accounts as essential to the company’s top-line momentum, noting t",
    "url": "https://finnhub.io/api/news?id=3b77dbf814753cdddae798ac56f8154b128408effb1b575b7faa10851b4c5a70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753767119,
      "headline": "5 Must-Read Analyst Questions From Quest’s Q2 Earnings Call",
      "id": 136130803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics delivered a quarter that surpassed Wall Street’s expectations, with strong results driven by a combination of acquisition contributions and robust organic growth. Management highlighted heightened demand for advanced diagnostic tests and expanded access through new health plan contracts as primary factors behind the performance. CEO Jim Davis pointed to increased test ordering from both physicians and enterprise accounts as essential to the company’s top-line momentum, noting t",
      "url": "https://finnhub.io/api/news?id=3b77dbf814753cdddae798ac56f8154b128408effb1b575b7faa10851b4c5a70"
    }
  }
]